M

Madrigal Pharmaceuticals

D
MDGL
USD
9.05
(3.8786%)
Market Closed
13,990.00
Volume
-27.26
EPS
-
Div Yield
-9.486497
P/E
5,262,718,651.26
Market Cap
Today
3.8786%
1 Week
3.136%
1 Month
-5.527%
6 Months
-8.598%
12 Months
43.200%
Year To Date
4.587%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
A
ALNY
3.06
(1.1203%)
USD
A
ARWR
0.35
(1.6851%)
USD
S
SRPT
1.96
(1.5667%)
USD
VRTX
VRTX
3.93
(0.8292%)
USD
REGN
REGN
11.33
(0.9948%)
USD
I
IONS
0.38
(0.8971%)
USD
R
RARE
1.17
(2.0316%)
USD
C
CRSP
-0.11
(-0.2219%)
USD
B
BLUE
-0.0046
(-0.9287%)
USD
B
BMRN
0.31
(0.4359%)
USD

Title:
Madrigal Pharmaceuticals

Sector:
Healthcare
Industry:
Biotechnology
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
Do you need help or have a question?
Contact Us